IVLEV, ANDREI VALENTINOVICH;LASKAVY, VLADISLAV NIKOLAEVICH
发明人:
LASKAVY, VLADISLAV NIKOLAEVICH
申请号：
BR112019003609
公开号：
BR112019003609A2
申请日:
2017.06.13
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
The invention generally relates to the field of veterinary medicine and may be used for prevention of bovine leukemia. The invention expands the media range of the claimed application and provides lifelong resistance to animals to leukemia virus. The invention aims to solve the problem of expanding the range of preventive drugs and to form new approaches to the problem of prevention of bovine leukemia, which enables the lifelong resistance of animals to leukemia infection. The technical result is the design of a drug and its use for the prevention of bovine leukemia, which would provide a targeted, efficient and low-cost immune response by activating cellular immunity against bovine leukemia virus by increasing the number of exterminating cells. The bovine leukemia prevention drug contains a water-soluble protein fraction of 18-20 kda molecular weight isolated from the products of mycobacterial destruction of tuberculosis characterized by the presence of peaks near a wavelength of 214 nm in the uv region. , a phosphate buffered saline, an aqueous formaldehyde solution and an isotonic sodium chloride solution. The use consists of administering the drug to calves aged 1 to 9 days with a single intramuscular injection at a dose of 4.0-6.0 ml per capita.a invenção geralmente se refere ao campo de medicina veterinária e pode ser usado para prevenção de leucemia bovina. a invenção expande a faixa dos meios da aplicação reivindicada e fornece a resistência vitalícia aos animais ao vírus da leucemia. a invenção tem o objetivo de resolver o problema de expandir a faixa de medicamentos preventivos e formar novas abordagens ao problema de prevenção de leucemia bovina, que possibilita garantir a resistência vitalícia dos animais a infecção por leucemia. o resultado técnico consiste do projeto de um remédio e seu uso para prevenção de leucemia bovina, que permitiria oferecer uma resposta imune direcionada, com eficiência e baixos custos, ativando a imunidade celular contra o vír
